AAPP member Steve Saklad co-authored the study that highlights key considerations for optimizing the use of aripiprazole monohydrate LAIs in clinical practice to enhance treatment outcomes in patients with schizophrenia and BP-I. Funding was provided by funding by Otsuka Pharmaceuticals Europe Ltd & H. Lundbeck A/S.